Green leaf pharmaceutical injection with acetate Gosherrin slow-release microsphere (LY01005) completes a human pharmacokinetic test in the United States
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
prostate cancer and breast cancer are among the most common cancers in the world among men and women, and are on the rise rapidlyRecently, Green leafPharmaceutical(http://Group announced that its self-developed innovative formulation injection with acetate Gosherin reprieve microsphere (LY01005) has completed a human pharmacokineticstest(http://in the United States, and reached the expected endIn addition, LY01005 has also entered a critical clinical trial phase in ChinaAbout LY01005
LY005 LY01005 is a gonadotropin-releasing hormone agonist used in the treatment of a variety of conditions such as prostate cancer, breast cancer and endometriosis, and is given by intramuscular injection at a monthly frequencyThis human pharmacokinetic test was conducted in 4 test bases in the United States, and the pharmacokinetics (PK), pharmacokinetics (PD) and safety indicators were evaluated by comparing it with the ® of the commercially available referencedrug(http://NorredThe results showed that there was no significant difference between LY01005 and Norede ® in the human body, but LY01005 had a more stable behavior of drug releaseIn addition, LY01005 has good safety and tolerance, no serious adverse events and adverse events that cause subjects to withdraw from the trial or death Next, Greenleaf Pharmaceuticals will communicate with the U.S Food and Drug Administration (
FDA (http:// on further development plans for LY01005 in the United States
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
